Navigation Links
Yves Lionel Assant is New Chairman of Gerresheimer's Supervisory Board
Date:9/25/2007

DUSSELDORF, Germany, September 25 /PRNewswire/ -- Yves Lionel Assant is the new Chairman of Gerresheimer's Supervisory Board, effective 24th of September, 2007.

Assant was already a member of the Supervisory Board. The current Chairman, Hans Peter Peters, has left the position for personal reasons. He remains a member of the Supervisory Board.

Gerresheimer is a pharmaceutical & life science supply and services company with market leading positions of specialty products made of glass and plastic. Gerresheimer owns 37 production sites in Europe, North America and Asia and employs approximately 10,000 employees worldwide.

Contact

Burkhard Lingenberg

Director Corporate PR & Marketing

Telefon +49-211-6181-250

Telefax +49-211-6181-241

e-mail b.lingenberg@gerresheimer.com

Internet http://www.gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Kyron appoints former AMA chairman to board
2. Third Wave appoints new chairman
3. Cisco Chairman donates $31 million for UW building renovation
4. Bone Care Names New Chairman
5. Cisco Chairman Praises University Research
6. Chemical-petroleum executive joins Virent Energy board
7. Schneider National exec joins TrafficCast board
8. Ethics Board site offers welcome contrast to state IT mistakes
9. Genomics researcher Hood joins NimbleGen board
10. Corporate control begins with a strong board
11. Online service makes board connections

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...IK, Iceland, November 24 ...nced the approval of all of its,"first day" motion... Delaware,(the "Bankruptcy Court"). deCODE last we...pter 11 of the United States Bankruptcy Code with ... by the Bankruptcy Court allow the company to cont...
(Date:11/24/2009)...24 /PRNewswire-Asia/ -- Shanghai Biolaxy announced...(SFDA) has approved the,investigational new drug a...lin), an innovative insulin formulation to treat d...ate its first phase I clinical study. , D... glucose and poor,metabolism. The complications of...
(Date:11/24/2009)...ndpoint has been met for patients with advanced-st...EBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEtern...ompany"), a global biopharmaceutical company focus...ced positive efficacy data from a Phase 2 study wi...108 (formerly AN-152), in patients with advanced o...
(Date:11/24/2009)...2009 Arena Pharmaceutica...he company is scheduled to present at the Piper Ja...er 1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. P...ork City. Jack Lief, Arena,s President and Chief E...iew of the company, including its clinical develop...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
...cts of Cost Savings Initiatives Quantified - ...dance -, HOPKINTON, Mass., April 24 Caliper Life...er of tools and services for,drug discovery and li...ented a plan to consolidate its west coast busines...improve productivity and effectiveness of,its rese...
...RY, N.J., April 24 Amicus Therapeutics,Inc. (Nasd... President and,Chief Executive Officer, will prese... Healthcare Unplugged Conference on Wednesday, Apr...in Key Biscayne, Florida., The presentation will ...icus, website at http://www.amicustherapeutics.co...
..., Pa., April 24 Cephalon, Inc.,(Nasdaq: CEPH ) t...fication,Notice Letter relating to an Abbreviated ...Food and Drug Administration (FDA) by Watson,Labor...ell a generic,version of FENTORA(R) (fentanyl bucc...leges that the U.S. Patent Numbers 6,200,604 and 6...
Other Biology Technology:Caliper Life Sciences Reports West Coast Consolidation of Operations 2Caliper Life Sciences Reports West Coast Consolidation of Operations 3Caliper Life Sciences Reports West Coast Consolidation of Operations 4Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 2Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 3
(Date:11/26/2009)...re some of the Ocean,s most distinctive residents....strange head shape, says Michelle McComb from Flo...he shark,s vision. ,Perhaps their visual field has...Comb, giving the sharks excellent stereovision and...here were two schools of thought on this theory. I...
(Date:11/26/2009)...t in eight European countries has shown that closi...andemic could have a significant role in reducing ...pen access journal BMC Infectious Diseases compa... weekends/holidays, finding that they were reduced...t and Antwerp University, Belgium, led a team of E...
(Date:11/26/2009)...esistant Staphylococcus Aureus ) and other drug-r...emperature plasma prototype devices have been deve...tericidal cocktails. , Two prototype devices hav...f healthy skin (e.g. hands and feet) in hospitals ... threat; and another to shoot bacteria-killing age...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2School closure could reduce swine flu transmission by 21 percent 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 1DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 3FDA Accepts Final Section of NDA Filing for LUCASSIN 28R 29 48733 1FDA Accepts Final Section of NDA Filing for LUCASSIN 28R 29 48733 2Volvo Invites Customers to Cut Their Service Bills While Supporting Pediatric Cancer Research 48729 1Volvo Invites Customers to Cut Their Service Bills While Supporting Pediatric Cancer Research 48729 2Volvo Invites Customers to Cut Their Service Bills While Supporting Pediatric Cancer Research 48729 3
...ltimore, MD) In the first neuroimaging study to e...searchers at the Kennedy Krieger Institute have un...l basis of autism. The study, published online in ...ss, compared the brain activity of children with h...ing peers while performing a simple motor tasktapp...
... biotechnologies that allow scientists to quickly ...le DNA analysis are being creatively deployed for ...isease. , The University of Ghana, supported by t... is pioneering the use of DNA "barcodes" to map me... lymphatic filariasis (LF), commonly known as elep...
...e human brain stores some kinds of memories for a ...t things, our gray matter also creates temporary m...the few seconds these visual memories exist. For d...memories don,t suddenly disappear, but grow gradua...nds. , Now researchers at the University of Calif...
Other Biology News:First neuroimaging study examining motor execution in children with autism reveals new insights 2First neuroimaging study examining motor execution in children with autism reveals new insights 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 2DNA barcoding of mosquito species deployed in bid to end elephantiasis 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 4Some short-term memories die suddenly, no fading 2
Goat Anti-T7 tag Polyclonal Antibody, Agarose Conjugated from GeneTex
Goat Anti-T7 Polyclonal Antibody, Agarose Conjugated from GeneTex
Rabbit Anti-Olfactory Receptor LS189744 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-C/EBPdelta Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: